Subject(s)
Atherosclerosis/therapy , Renal Artery Obstruction/therapy , Angioplasty, Balloon , Atherosclerosis/complications , Atherosclerosis/drug therapy , Cardiovascular Diseases/etiology , Cardiovascular Diseases/prevention & control , Humans , Hypertension, Renovascular/etiology , Outcome Assessment, Health Care , Patient Selection , Randomized Controlled Trials as Topic , Renal Artery Obstruction/complications , Renal Artery Obstruction/drug therapy , StentsSubject(s)
Renal Artery Obstruction/therapy , Angioplasty, Balloon/adverse effects , Humans , Hypertension, Renovascular/prevention & control , Practice Guidelines as Topic , Randomized Controlled Trials as Topic , Renal Artery Obstruction/complications , Renal Artery Obstruction/drug therapy , Renal Artery Obstruction/surgery , Stents , Treatment OutcomeABSTRACT
Antihypertensive treatment reduces the risk of thromboembolic events in hypertension. The aim of this study was to examine the influence of angiotensin-converting enzyme inhibition on blood coagulation in subjects with mild-to-moderate essential hypertension. Fibrinogen, thrombin-antithrombin complex (TAT) and Factor VII were determined in plasma at rest and after a mental stress test following placebo for 6 weeks, or ramipril for 6 weeks or 6 months. Ramipril reduced resting TAT, and tended to reduce fibrinogen; Factor VII remained unchanged. Mental stress increased fibrinogen, but did not alter TAT or Factor VII activity. The reduced thrombin generation in patients taking ramipril may explain in part why angiotensin-converting enzyme inhibitors reduce thromboembolic complications in patients with cardiovascular disease.
